Dr. Mukherjee explores the future of antibody-drug conjugates in GI cancers, emphasizing precision medicine and targeted therapies for optimal patient outcomes.
Sarbajit Mukherjee, MD
Articles by Sarbajit Mukherjee, MD
Clinicians explore the shift towards earlier use of antibody-drug conjugates in GI oncology, aiming to enhance patient outcomes and treatment efficacy.
Explore the vital role of antibody-drug conjugates in precision oncology for GI malignancies, focusing on managing payload-dependent toxicities effectively.
Discover how antibody-drug conjugates (ADCs) are transforming treatment strategies for gastrointestinal cancers, enhancing precision and patient outcomes.
Latest Updated Articles
ADCs Could Move Up the Treatment Line in GI CancersPublished: February 4th 2026 | Updated:
Building Better ADCs for GI Cancers: Targets, Timing, and ToxicitiesPublished: February 2nd 2026 | Updated:
- Payload-Driven Toxicities: Clinical Red Flags in Patients Receiving ADCs
Published: February 3rd 2026 | Updated: